Overview

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is the first-in-human clinical study to see if a single dose of an investigational nasal spray made from a modified plant protein called Q-Griffithsin is safe, tolerated and acceptable for use by healthy adults 18 to 60 years of age.
Phase:
Phase 1
Details
Lead Sponsor:
Kenneth Palmer
Collaborator:
United States Department of Defense